Raymond James Financial
ADMA icon

Raymond James Financial’s ADMA Biologics ADMA Stock Holding History

Raymond James Financial’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.07M Sell
367,114
-283,875
-44% -$2.59M ﹤0.01% 3158
2026
Q1 		$5.87M Sell
650,989
-362,753
-36% -$5.72M ﹤0.01% 2462
2025
Q4 		$18.5M Sell
1,013,742
-238,054
-19% -$4.01M 0.01% 1508
2025
Q3 		$18.4M Sell
1,251,796
-270,249
-18% -$4.63M 0.01% 1474
2025
Q2 		$27.7M Buy
1,522,045
+202,242
+15% +$4.12M 0.01% 1132
2025
Q1 		$26.2M Buy
1,319,803
+207,528
+19% +$3.59M 0.01% 1108
2024
Q4 		$19.1M Buy
+1,112,275
New +$20.9M 0.01% 1354

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Raymond James Financial's ADMA Position: Q2 2026 in Review

Raymond James Financial reduced its ADMA Biologics (ADMA) stake by 44% in Q2 2026, selling an estimated $2.59M and leaving 367,114 shares worth $3.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3158.

Raymond James Financial first reported a position in ADMA in Q4 2024 and has held it in 7 quarters since. The position peaked at $27.7M in Q2 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Raymond James Financial held 367,114 shares of ADMA Biologics worth $3.07M as of Q2 2026.
  • Raymond James Financial sold 283,875 ADMA Biologics shares in Q2 2026, an estimated $2.59M.
  • ADMA Biologics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3158 holding.
  • Raymond James Financial first reported a position in ADMA Biologics in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's ADMA Biologics position peaked at $27.7M in Q2 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.